Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EST Cathie Wood’s ARK Investment buys 120K shares of 10x Genomics (TXG) today Published first on TheFly – the ultimate source for real-time, ...

10x Genomics (NASDAQ:TXG) stock slid 14% Wednesday amid news that Illumina (ILMN) has acquired single cell analysis technology company Fluent BioSciences and a downgrade by Deutsche Bank.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.84 which represents a decrease of $-0.01 or -0.07% from the prior close of $14.85. The stock opened at $14.99 and touched a low of ...

Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.41 which represents a decrease of $-0.04 or -0.28% from the prior close of $14.45. The stock opened at $14.25 and touched a low of ...

10x Genomics excels in single-cell and spatial technologies but faces significant challenges. Despite an EPS beat, revenue fell 1% due to sales disruption and competitive pricing. The company's ...

Furthermore, the services segment experienced robust year-over-year and quarter-over-quarter growth, showcasing 10x Genomics’s ability to expand its offerings and enhance its market position.